Amylyx Pharmaceuticals, Inc. $AMLX Stock Purchased by Moody Aldrich Partners LLC

Key Points

• Moody Aldrich Partners increased its Amylyx Pharmaceuticals stake by 198.3% in the third quarter, adding 114,618 shares to own 172,420 shares valued at approximately $5.0 million. Institutional investors and hedge funds collectively own 95.84% of AMLX.
• Analyst sentiment is generally positive: AMLX has a consensus “Moderate Buy” rating and an average price target of $40.71, with several firms recently raising targets. However, one analyst maintains a sell rating.
• Company insiders sold shares during the latest quarter, including CFO James Frates and Director George Milne Jr.; total insider sales reached 60,374 shares worth about $1.82 million. Amylyx also reported a quarterly loss of $0.39 per share, slightly worse than estimates.

Moody Aldrich Partners LLC increased its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 198.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 172,420 shares of the company's stock after acquiring an additional 114,618 shares during the quarter. Moody Aldrich Partners LLC owned approximately 0.15% of Amylyx Pharmaceuticals worth $5,017,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter worth about $158,534,000. Jupiter Topco LLC acquired a new stake in Amylyx Pharmaceuticals in the 2nd quarter worth about $94,014,000. Siren L.L.C. purchased a new stake in Amylyx Pharmaceuticals during the 1st quarter worth approximately $17,097,000. Alyeska Investment Group L.P. purchased a new stake in Amylyx Pharmaceuticals during the 2nd quarter worth approximately $18,912,000. Finally, Almitas Capital LLC purchased a new stake in Amylyx Pharmaceuticals during the 2nd quarter worth approximately $17,509,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AMLX shares. Robert W. Baird lifted their price target on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 19th. Wolfe Research upgraded Amylyx Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 17th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Mizuho upped their target price on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an "outperform" rating in a report on Tuesday, August 18th. Finally, Guggenheim upped their target price on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a "buy" rating in a report on Thursday, August 27th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $40.71.

Insider Activity at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CFO James M. Frates sold 10,810 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $32.36, for a total transaction of $349,811.60. Following the completion of the transaction, the chief financial officer owned 233,625 shares of the company's stock, valued at $7,560,105. This trade represents a 4.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George M. Milne, Jr. sold 30,000 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $27.70, for a total transaction of $831,000.00. Following the transaction, the director directly owned 782,881 shares of the company's stock, valued at approximately $21,685,803.70. This trade represents a 3.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 60,374 shares of company stock valued at $1,815,257 in the last quarter. Corporate insiders own 10.90% of the company's stock.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock opened at $28.07 on Thursday. Amylyx Pharmaceuticals, Inc. has a 12 month low of $10.83 and a 12 month high of $41.14. The company has a market capitalization of $3.13 billion, a PE ratio of -19.63 and a beta of -0.10. The firm's 50-day moving average is $31.31 and its two-hundred day moving average is $19.88.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.03). Sell-side analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current year.

About Amylyx Pharmaceuticals

Want to see what other hedge funds are holding AMLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.